Your browser doesn't support javascript.
loading
Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.
Hsu, Shih-Jer; Enkhzaya, Sukhee; Lin, You-Yu; Tseng, Tai-Chung; Khosbayar, Tulgaa; Tsai, Cheng-Hsueh; Wang, Tzu-San; Enkhtuya, Damba; Ivshinkhorol, Dogsom; Naranzul, Nyamsuren; Jargalsaikhan, Badarch; Amarsanaa, Jazag; Baatarkhuu, Oidov; Kao, Jia-Horng.
Afiliação
  • Hsu SJ; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan; Hepatology Medical Center, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
  • Enkhzaya S; Department of Infectious Disease, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia; Department of Comprehensive Laboratory, National Center for Communicable Diseases, Ulaanbaatar, Mongolia.
  • Lin YY; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Tseng TC; Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Khosbayar T; Department of Molecular Biology and Genetics, School of BioMedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
  • Tsai CH; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Wang TS; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Enkhtuya D; Happy Veritas Liver Diagnostic Center, Ulaanbaatar, Mongolia.
  • Ivshinkhorol D; Happy Veritas Liver Diagnostic Center, Ulaanbaatar, Mongolia.
  • Naranzul N; Department of Infectious Disease, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
  • Jargalsaikhan B; Department of Obstetrics and Gynecology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
  • Amarsanaa J; Mongolian Association for the Study of Liver Diseases, Mongolia.
  • Baatarkhuu O; Department of Infectious Disease, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia; Department of Comprehensive Laboratory, National Center for Communicable Diseases, Ulaanbaatar, Mongolia; Mongolian Association for the Study of Liver Diseases, Mongolia. E
  • Kao JH; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan;
J Formos Med Assoc ; 119(3): 712-719, 2020 Mar.
Article em En | MEDLINE | ID: mdl-31672433
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C Crônica / Farmacorresistência Viral Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: J Formos Med Assoc Assunto da revista: MEDICINA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Taiwan País de publicação: Singapura
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C Crônica / Farmacorresistência Viral Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: J Formos Med Assoc Assunto da revista: MEDICINA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Taiwan País de publicação: Singapura